Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.53 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
| ▸ | DDT | P30046 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440126 | 0.93 | DDT (0.51) | CCR1ELANEPLA2G10DDT | |
| SCHEMBL5440460 | 0.90 | ELANE (0.54) | CCR1ELANEPLA2G10DDT | |
| SCHEMBL5757939 | 0.85 | ELANE (0.65) | CCR1ELANEDDTEPHX2 | |
| SCHEMBL5444649 | 0.84 | ELANE (0.49) | CCR1ELANEPLA2G10 | |
| SCHEMBL5445075 | 0.84 | ELANE (0.52) | CCR1ELANEPLA2G10 | |
| SCHEMBL5443539 | 0.84 | SORT1 (0.56) | CCR1ELANEPLA2G10 | |
| SCHEMBL561233 | 0.84 | ELANE (0.52) | CCR1ELANEDDT | |
| SCHEMBL31490267 | 0.84 | ELANE (0.52) | CCR1ELANEDDT | |
| SCHEMBL5434666 | 0.83 | ELANE (0.55) | CCR1ELANEPLA2G10MEN1NPC1 | |
| SCHEMBL5441836 | 0.83 | ELANE (0.54) | CCR1ELANEPLA2G10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1660452-A1 | QUINOLINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021509-A1 | QUINOLINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | CCR1 200/4885ELANE 2/4885PLA2G10 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.